Recent Quotes (30 days)

You have no recent quotes
chg | %

Clinigen Group PLC  

(Public, LON:CLIN)   Watch this stock  
+5.88 (1.18%)
Jan 29 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 498.00 - 513.16
52 week 354.92 - 690.00
Open 500.00
Vol / Avg. 2.20M/196,180.00
Mkt cap 412.26M*
P/E 26.42
Div/yield 2.10/0.62*
EPS 0.19*
Shares 82.56M
Beta     -
Inst. own     -

Key stats and ratios

Q2 (Jun '14) 2014
Net profit margin 13.91% 12.80%
Operating margin 18.24% 16.99%
EBITD margin - 21.18%
Return on average assets 18.65% 17.66%
Return on average equity 29.14% 27.65%
Employees 107 -
CDP Score - -


Pitcairn House Crown Square, Centrum 100 BURTON ON TRENT
United Kingdom - Map
+44-1283-494340 (Phone)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance


Clinigen Group plc (Clinigen) is a specialty pharmaceuticals and services business company. The Company operates in three segments: Clinical Trial Supply, Specialty Pharmaceuticals and Global Access Programs. Clinical Trial Supply division is involved in the sourcing and supply of comparator products for Clinical Trials. Specialty Pharmaceuticals division is involved in the manufacture and distribution of pharmaceutical products. Global Access Programs division provides on-going access to patients involved in clinical trials through the management of Access Programs. The Company�s subsidiaries include Clinigen Healthcare Limited, Keats Healthcare Limited, Clinigen CTS Inc, Clinigen Pharma Limited, Clinigen Clinical Trials Limited, Clinigen CTS Limited and Clinigen GAP Limited. In March 2013, the Company announced the acquisition of Cardioxane (dexrazoxane).

Officers and directors

Peter Lutz George Chief Executive Officer, Director
Robin Andrew John Sibson Chief Financial Officer, Secretary, Director
Shaun Edward Chilton Chief Operating Officer, Director
Age: 45
Paul Thomas Chief Technical Officer
Peter Vance Allen Independent Non-Executive Chairman of the Board
Age: 57
John Hartup Independent Non-Executive Director
Ian J. Nicholson MBA Independent Non-Executive Director